We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




When Exercise Is Unhealthy: Study Sheds New Light on Sudden Cardiac Death

By LabMedica International staff writers
Posted on 30 Dec 1899
Researchers have discovered new aspects, involving a mutated protein, of a not-well-understood mechanism that underlies how sudden heart failure can occur during endurance exercise in patients with arrhythmogenic ventricular cardiomyopathy (AVC), which currently has no standardized guidelines for exercise management. More...
The findings may inform development of early diagnostics, drug treatments, and personalized exercise programs.

AVC is the most common heart condition that causes sudden cardiac death during intense exercise. Using various analyses of cardiac function and morphology, a team led by Jeffrey A. Towbin, MD, of the University of Tennessee Health Science Center (Memphis, TN, USA), in collaboration with researchers from Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) and others has found that in mice with a known mutated version of desmoplakin, a protein that helps maintain the structure of the heart wall, exercise made the heart walls come apart sooner, leading to earlier development of AVC.

Heart wall cells are stacked in interlocking layers attached to each other by desmosomes that dot the surface of the cells. Exercise can overstretch the heart wall, but these intercellular links keep the cells from disconnecting from each other and prevent the heart wall from coming apart. Desmosomes are made up of several proteins, including desmoplakin. Defects can weaken the cell-cell links, as in AVC, such that the cells do not withstand the extra stretch from exercise and so detach from each other. Scar tissue fills the gaps between the disconnected cells, further reducing the wall’s ability to withstand increased workload as in exercise.

Several studies observed that mice with a mutated form of desmoplakin developed the same heart problems seen in patients with AVC. In this new study, in addition to finding that endurance exercise led to earlier onset of AVC symptoms in the mice with the mutated desmoplakin, the researchers also discovered that the desmosomes started coming apart before changes in heart function were detected and that exercise perturbed AKT1 and GSK3-β signaling in the Wnt-β-catenin pathway, which promotes growth of new cells and prevents deposition of fat, offering an explanation for the accelerated development of AVC.

The study suggests that changes in the cell-cell links can be detected before alterations in heart function occur. This could help identify individuals with the mutation before they develop AVC symptoms, said Dr. Towbin, opening the possibility of better strategies to prevent exercise-induced complications and of developing drugs targeting the Wnt-β-catenin pathway to potentially help AVC patients.

The study, by Martherus R et al., was published online ahead of print November 6, 2015, in the American Journal of Physiology — Heart & Circulatory Physiology.

Related Links:

University of Tennessee Health Science Center
Cincinnati Children’s Hospital Medical Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.